The CORALreef Lipids trial found that enlicitide, an oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% compared to placebo. Treatment also improved apolipoprotein B and lipoprotein(a) levels. The drug was well-tolerated with safety results similar to placebo. Powered by <a href="https://firstory.me/zh">Firstory Hosting</a>

The CORALreef Lipids trial found that enlicitide, an oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% compared to placebo. Treatment also improved apolipoprotein B and lipoprotein(a) levels. The drug was well-tolerated with safety results similar to placebo. Powered by Firstory Hosting

The CORALreef Lipids trial found that enlicitide, an oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% compared to placebo. Treatment also improved apolipoprotein B and lipoprotein(a) levels. The drug was well-tolerated with safety results similar to placebo. Powered by <a href="https://firstory.me/zh" rel="noopener noreferrer">Firstory Hosting</a>

Oral PCSK9 Inhibition with Enlicitide for LDL Cholesterol Reduction

It's a podcast discussing recent exciting scientific findings in biology and medicine. Powered by <a href="https://firstory.me/zh">Firstory Hosting</a>

Science

Medicine

Health & Fitness

Education

Life Sciences

It's a podcast discussing recent exciting scientific findings in biology and medicine. Powered by Firstory Hosting

It's a podcast discussing recent exciting scientific findings in biology and medicine. Powered by <a href="https://firstory.me/zh" rel="noopener noreferrer">Firstory Hosting</a>

Share Oral PCSK9 Inhibition with Enlicitide for LDL Cholesterol Reduction

Sign up to save your podcasts

Oral PCSK9 Inhibition with Enlicitide for LDL Cholesterol Reduction

Oral PCSK9 Inhibition with Enlicitide for LDL Cholesterol Reduction